



BC PharmaCare Newsletter

July 28, 2015 Edition 15-008

Published by the Medical Beneficiary and Pharmaceutical Services Division to provide information for British Columbia’s health care providers

QuickLinks

Exchange Rate Update—for Prosthetic Suppliers.....	1
Maintaining Your Enrollment	2
Provider Duties and Obligations	2
Change Form Available Online—Reminder.....	2
Correct Quantities for Claims	2
Benefits	2
Special Authority Coverage Updates.....	2
Benefit Tables	3

EXCHANGE RATE UPDATE—FOR PROSTHETIC SUPPLIERS

New U.S. Exchange Rate \$1.2652*

*Based on the [Bank of Canada](#) rate at the close of business on July 6, 2015.

The price list for prosthetic components is adjusted, as needed, based on the U.S. Exchange Rate published by the Bank of Canada.

Rates are reviewed regularly and adjusted whenever the rate changes by more than five cents and remains at a variance of five cents or more for at least five working days.

The use of PharmaNet is not intended as a substitute for professional judgment. Information on PharmaNet is not exhaustive and cannot be relied upon as complete.

The absence of a warning about a drug or drug combination is not an indication that the drug or drug combination is safe, appropriate or effective in any given patient. Health care professionals should confirm information obtained from PharmaNet, and ensure no additional relevant information exists, before making patient care decisions.



Ministry of Health

To subscribe or unsubscribe from our newsletter notification list, or to find out more about our programs, visit PharmaCare on the Web: www.gov.bc.ca/pharmacare

MAINTAINING YOUR ENROLLMENT

Provider Duties and Obligations

Approved PharmaCare providers are required to abide by PharmaCare policies as published in PharmaCare policy manuals and in PharmaCare Newsletters and PharmaNet Bulletins.

In your Welcome Package, under the heading *Your Duties and Obligations*, you will find more detailed information on the act, regulations, policies and procedures that govern all PharmaCare providers. It also explains your obligation to notify PharmaCare of specific business changes.

Please read the information. It is critical to maintaining your standing with the PharmaCare program. Failure to abide by your duties and obligations may result in delay or suspension of payments.

Change Form Available Online—Reminder

As outlined in the [Enrollment Guide](#), the Provider Regulation requires providers to notify Health Insurance BC of changes in their enrollment information.

Use the [PharmaCare Provider Change \(HLTH 5433\)](#) to report any future changes to your enrollment information.

To submit a change, complete the first page of the form and any relevant parts (A through K) required.

Important: Failure to abide by your duties and obligations may result in delay or suspension of payments.

Provider Enrollment Resources

All enrollment information, including the Enrollment Guide, enrollment forms, and the PharmaCare Provider Change form are available on the Pharmacy Provider web page (www.gov.bc.ca/pharmacarepharmacists) and the Device Provider web page (www.gov.bc.ca/pharmacaredeviceproviders).

CORRECT QUANTITIES FOR CLAIMS

Need a list of the correct quantities to use when submitting claims for many commonly prescribed injectable medications and other products? See our [regularly updated list](#).

Have a suggestion for an addition to this list? E-mail your suggestions to pharma@gov.bc.ca.

BENEFITS

Special Authority Coverage Updates

Ombitasvir/paritaprevir/ritonavir and dasabuvir (Holkira™ Pak) for chronic hepatitis C virus genotype 1 infection

Effective **July 28, 2015**, PharmaCare will cover ombitasvir/paritaprevir/ritonavir and dasabuvir (Holkira™ Pak) through the Special Authority (SA) program under the following Limited Coverage criteria:

- For the treatment of chronic hepatitis C virus (HCV) genotype 1 infection, with or without ribavirin (Moderiba™), in treatment-naïve and treatment-experienced patients with compensated liver disease (with no cirrhosis or with compensated cirrhosis).

Subscribe!

NEWSLETTERS/BULLETINS

To receive an e-mail whenever a new edition is published, subscribe at www.gov.bc.ca/pharmacarenewsletter

Note: PharmaCare is not providing coverage of Moderiba. Please see below article on Access to Ribavirin (Moderiba) through AbbVie Care.

Please also note that ribavirin (Ibavyr™) will continue to be an eligible PharmaCare benefit for patients that require this medication in combination with other treatments for chronic HCV infections.

For the detailed coverage criteria, SA Request forms, and other information for Holkira Pak, see [ombitasvir/paritaprevir/ritonavir and dasabuvir](#).

Actual reimbursement is subject to the rules of a patient's PharmaCare plan, including any annual deductible requirement. Retroactive coverage cannot be provided for prescriptions filled before SA approval is in place.

A prescriber letter regarding coverage of drugs for HCV infections will be mailed to practicing infectious disease specialists, gastroenterologists, and to general practitioners.

Access to Ribavirin (Moderiba™) through AbbVie Care

Ribavirin (Moderiba™) is indicated in combination with Holkira Pak for the treatment of HCV infection in adults including patients with compensated cirrhosis.

PharmaCare is not providing coverage of Moderiba, however, Moderiba is provided through the AbbvieCare patient support program when prescribed in combination with ombitasvir-paritaprevir-ritonavir and dasabuvir (Holkira™ Pak). Patients can enroll in AbbVie Care through their physician's office and AbbVie Care will coordinate distribution of Moderiba through pharmacies.

Entering claims for Moderiba

Pharmacists must enter an intervention code to ensure a claim for Moderiba will not be adjudicated by PharmaCare:

- In the **Drug Cost** field, enter **zero**.
- In the **Dispensing Fee** field, enter **zero**.
- Enter the Intervention Code **DE—Adjudicate to zero**.

Benefit Tables

Limited Coverage Drug Program

The following products are eligible benefits under the Limited Coverage Program—by Special Authority only—for Fair PharmaCare and Plans B, C, and F. For the Special Authority criteria, please visit the [Special Authority Information](#) page on the PharmaCare website.

DIN	DRUG NAME	PLAN G	PLAN P
02436027	Holkira™ Pak (ombitasvir/paritaprevir/ritonavir and dasabuvir) 12.5 mg/75 mg/50 mg and 250 mg tablet	N	N

Non-Benefits

The following products have been reviewed and will not be added as benefits under PharmaCare.

DIN	DRUG NAME
02436396	Moderiba™ (ribavirin) 200 mg tablet
02436418	Moderiba™ (ribavirin) 400 mg tablet
02436426	Moderiba™ (ribavirin) 600 mg tablet
02361825	Revolade® (eltrombopag olamine) 25mg tablet
02361833	Revolade® (eltrombopag olamine) 50mg tablet
02423049	Revolade® (eltrombopag olamine) 75 mg tablet